Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. The company supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). The company supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The company supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue
3,349
3,349
3,156
2,875
2,517
2,553
Revenue Growth (YoY)
6%
6%
10%
14%
-1%
9%
Cost of Revenue
1,892
1,892
1,708
1,468
1,252
1,252
Gross Profit
1,457
1,457
1,448
1,407
1,265
1,301
Selling, General & Admin
566
566
568
544
509
488
Research & Development
151
151
141
149
144
143
Operating Expenses
779
715
819
785
756
742
Other Non Operating Income (Expenses)
71
--
-84
-14
-11
-13
Pretax Income
602
602
455
281
233
544
Income Tax Expense
112
112
93
89
42
124
Net Income
485
485
359
190
188
421
Net Income Growth
35%
35%
89%
1%
-55%
-2%
Shares Outstanding (Diluted)
222.93
222.68
223.49
222.36
225
233
Shares Change (YoY)
0%
0%
1%
-1%
-3%
-2%
EPS (Diluted)
2.18
2.18
1.61
0.85
0.84
1.81
EPS Growth
35%
35%
89%
1%
-54%
0%
Free Cash Flow
119
119
329
404
305
409
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
43.5%
43.5%
45.88%
48.93%
50.25%
50.95%
Operating Margin
20.24%
22.15%
19.93%
21.63%
20.22%
21.89%
Profit Margin
14.48%
14.48%
11.37%
6.6%
7.46%
16.49%
Free Cash Flow Margin
3.55%
3.55%
10.42%
14.05%
12.11%
16.02%
EBITDA
916
980
797
881
881
704
EBITDA Margin
27.35%
29.26%
25.25%
30.64%
35%
27.57%
D&A For EBITDA
238
238
168
259
372
145
EBIT
678
742
629
622
509
559
EBIT Margin
20.24%
22.15%
19.93%
21.63%
20.22%
21.89%
Effective Tax Rate
18.6%
18.6%
20.43%
31.67%
18.02%
22.79%
Follow-Up Questions
What are Hikma Pharmaceuticals PLC's key financial statements?
According to the latest financial statement (Form-10K), Hikma Pharmaceuticals PLC has a total asset of $5,671, Net profit of $485
What are the key financial ratios for HKMPY?
Hikma Pharmaceuticals PLC's Current ratio is 1.84, has a Net margin is 14.48, sales per share of $15.03.
How is Hikma Pharmaceuticals PLC's revenue broken down by segment or geography?
Hikma Pharmaceuticals PLC largest revenue segment is Injectables, at a revenue of 1,022,059,311 in the most earnings release.For geography, United States is the primary market for Hikma Pharmaceuticals PLC, at a revenue of 1,476,742,665.
Is Hikma Pharmaceuticals PLC profitable?
yes, according to the latest financial statements, Hikma Pharmaceuticals PLC has a net profit of $485
Does Hikma Pharmaceuticals PLC have any liabilities?
yes, Hikma Pharmaceuticals PLC has liability of 3,078
How many outstanding shares for Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC has a total outstanding shares of 221.88